Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
| ▸ | ACVR1B | P36896 | 9/20 | 0.44 |
| ▸ | ACVRL1 | P37023 | 8/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.44 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16888489 | 0.87 | TGFBR1 (0.55) | TGFBR1CYP3A4CYP2C8ACVR1BACVRL1 | |
| SCHEMBL18221548 | 0.86 | TGFBR1 (0.48) | TGFBR1CYP3A4CYP2C8ACVR1BACVRL1 | |
| SCHEMBL18219788 | 0.76 | MAPK14 (0.35) | TGFBR1CYP3A4ACVR1BACVRL1ACVR1 | |
| SCHEMBL18219787 | 0.74 | NUDT1 (0.47) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL22270337 | 0.72 | TGFBR1 (0.79) | TGFBR1CYP3A4CYP2C8ACVR1BACVRL1 | |
| SCHEMBL22270338 | 0.71 | TGFBR1 (0.79) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL16888490 | 0.70 | TGFBR1 (0.40) | TGFBR1CYP3A4ACVR1BACVRL1ACVR1 | |
| SCHEMBL16879386 | 0.69 | TGFBR1 (0.82) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL16879337 | 0.69 | TGFBR1 (0.66) | TGFBR1ACVR1BACVRL1ACVR1 | |
| SCHEMBL18219797 | 0.68 | TGFBR1 (0.84) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702401-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-20180208577-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-07-26 | — | — | US | disclosed |
| US-10030004-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2018-07-24 | — | — | US | disclosed |
| US-20160326137-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702401-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | TGFBR1 13/4885CYP3A4 4780/4885CYP2C8 4349/4885 |
| US-10030004-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | TGFBR1 13/4885CYP3A4 4780/4885CYP2C8 4349/4885 |
| US-20160326137-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | TGFBR1 13/4885CYP3A4 4780/4885CYP2C8 4349/4885 |
| US-20180208577-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | TGFBR1 13/4885CYP3A4 4780/4885CYP2C8 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.